Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 7 | Chimagen Biosciences, LtdINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04517435 |
| ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| terminated |
| Phase 1 / Phase 2 |
| 13 |
| Deepa JagadeeshOTHER |
| 1 |
| Feb 7, 2025 |
| clinicaltrials |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | terminated | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05096234 | 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma | terminated | Phase 1 | 2 | Stanford UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | terminated | Phase 1 | 4 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | terminated | Phase 1 | 16 | Lava TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT03248479 | Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | terminated | Phase 1 | 258 | Gilead SciencesINDUSTRY | 2 | Jan 17, 2025 | clinicaltrials |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | terminated | Phase 1 | 49 | CRISPR Therapeutics AGINDUSTRY | 3 | Jan 8, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | terminated | Phase 1 | 83 | Seagen Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | terminated | Phase 1 | 27 | Celularity IncorporatedINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | terminated | Phase 1 | 11 | Guenther KoehneOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04282668 | A Study of TAS1440 With ATRA in Subjects With r/r AML | terminated | Phase 1 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | terminated | Phase 1 | 14 | ALX Oncology Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | terminated | Phase 1 / Phase 2 | 109 | TakedaINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 19 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 9 | Cartesian TherapeuticsINDUSTRY | 2 | Nov 12, 2024 | clinicaltrials |
| NCT04060849 | Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY | terminated | Phase 1 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT02610062 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 23 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 16 | iTeos TherapeuticsINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT02864290 | A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Oct 23, 2024 | clinicaltrials |
| NCT02270463 | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | terminated | Phase 1 / Phase 2 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04860466 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 9 | CelgeneINDUSTRY | 4 | Oct 16, 2024 | clinicaltrials |
| NCT03541369 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia(20170528) | terminated | Phase 1 | 64 | AmgenINDUSTRY | 6 | Oct 10, 2024 | clinicaltrials |
| NCT03710915 | A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 3 | HitGen Inc.INDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 6 | Oct 4, 2024 | clinicaltrials |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | terminated | Phase 1 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02099539 | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 19 | Altor BioScienceINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02509039 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 | 10 | Hackensack Meridian HealthOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | terminated | Phase 1 / Phase 2 | 23 | Suzanne Lentzsch, MDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03735875 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | terminated | Phase 1 | 7 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | terminated | Phase 1 | 4 | Medical College of WisconsinOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05682170 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 40 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | terminated | Phase 1 | 11 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 1 | BioLineRx, Ltd.INDUSTRY | 6 | Sep 5, 2024 | clinicaltrials |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 47 | CelgeneINDUSTRY | 5 | Aug 30, 2024 | clinicaltrials |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | terminated | Phase 1 | 53 | Hoffmann-La RocheINDUSTRY | 6 | Aug 23, 2024 | clinicaltrials |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 58 | Columbia UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 13, 2025source: clinicaltrials